Biofourmis harnesses the power of technology and data to shape innovations that bring the right care to every person, no matter where they are. The company aims to make care simpler, science smarter, and patients healthier.

Xuejiao Zhao

Kuldeep Rajput

Maulik Majmudar

Biofourmis

Cezar Health is involved in the medical equipment and healthcare industry, providing products and services related to hospitals, dental units, and consumer health. The company self-described as a participant in various healthcare conferences and has launched its own private label brand in the health sector.

Cezar Health

Joint Medical Company provides a comprehensive catalog of medical products and services across the spectrum, from injection syringes to advanced diagnostic instruments and hospital equipment. The company aims to improve medical outcomes and preserve health.

Joint Medical Company

Synergy CHC Corp is a consumer health care company. It is in the business of marketing and distributing consumer branded products through various distribution channels primarily in the health and wellness industry. The company's products include FOCUSfactor, Flat Tummy Tea, Hand MD, and Neuragen amongst others. Synergy generates the majority of its revenue from the sale of Flat Tummy Tea, which is exclusively sold online at www.flattummyco.com. Flat Tummy Tea is a uniquely formulated two-step herbal detox tea that works to naturally help speed metabolism, boost energy and reduce bloating.

Synergy CHC Corp.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. 

Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. 

Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.

Aviva Ventures

SGInnovate

Jianke

Openspace

SoftBank Vision Fund

Sequoia Capital

Capikris Foundation

MMV Europe & Asia-Pacific

EDBI

Intel Capital

General Atlantic

CVS Health

Looking for exciting things happening at ViVE 2024 next week?

Stop by Biofourmis booth #1924 to learn more about new advancements to our solutions that are revolutionizing the delivery of care and drug development across the care continuum. And while you’re there, be sure to pick up some chocolate espresso beans for a ViVE re-fuel.

Join us for engaging panels featuring Biofourmis’ leaders Maulik Majmudar, M.D. and Ross Armstrong throughout the week around strategies for building and scaling digital health technologies.

Follow us here for more updates 👀 throughout the week! See you in LA.

Check out the full ViVE schedule here: https://lnkd.in/dXn_xbgK I #ViVE2024 #ViVE24 #DigitalHealth #HealthcareInnovation

By improving the participant selection and enrollment process through automated and fully digital screening, as well as nurturing engagement throughout with easy-to-use and non-intrusive technology, biopharma can build and sustain more relevant cohorts that deliver more meaningful and instructive results regardless of the trial phase. 

Biofourmis COO Jaydev Thakkar forecasts what’s ahead for clinical trials with Citeline Commercial: https://lnkd.in/eB97zS8P I #DigitalClinicalTrials #HybridClinicalTrials #DigitalHealth #Pharma #ClinicalTrials #ClinicalTrialEnrollment

Remote patient management technologies have experienced a 1300% increase in claim volumes from 2019 to 2023. 

However, the accelerating pace of RPM technology has outpaced its administrative framework, as highlighted in a recent Bipartisan Policy Center report. The future success of remote monitoring lies in bridging these gaps, ensuring that these cutting-edge devices reach the patients who need them most. The report urges policymakers, payers, and providers to refine their approach now, seizing the opportunity to maximize the safe and appropriate adoption of RPM technology.

By collaborating on these opportunities, stakeholders can usher in a new era of high-value RPM devices at scale, to achieve shared goals of lower costs, better outcomes, and better experiences for people with chronic conditions. 

https://lnkd.in/g7jJpbKP I #RemotePatientMonitoring #RemotePatientManagement #DigitalHealth #VirtualCare #ChronicDiseaseManagement #DigitalDiseaseManagement Digital Health Insights

In this DPHARM: Disruptive Innovations to Advance Clinical Trials webcast, experts from Biofourmis, Advarra, IQVIA, Science 37, and Bayer join Merck's Katherine Taylor to discuss:

 ▶ Interoperability of technology to lessen burden for sites.

 ▶ More intentional implementation of technologies for easier patient access.

 ▶ Harnessing the good, the bad, and the concerning of generative AI for clinical development.

 ▶ Running a fully remote trial with confidence for patients and investigators.

Watch it here: https://lnkd.in/e5gSzzgz I #ClinicalTrials #ArtificialIntelligence #Interoperability #ClinicalTrialDesign #HybridClinicalTrials #DigitalHealth Jaydev Thakkar

Biofourmis’ Howard Levy and Jeremy Maltz recently had the privilege of participating in a panel discussion hosted by Okta at the Legacy Club of Boston. 
 
Led by Okta’s Justin Thorne, the panel focused on dismantling organizational silos to prioritize end-user security and achieve collective success. A special moment for participants was when Geoff W., AVP at Okta, introduced Brad Marchand, captain of the Boston Bruins, who shared wisdom about team dynamics in professional sports, underscoring the importance of effective team collaboration. 🏒
 
We would like to extend our heartfelt thank you to Okta for hosting us and to everyone who joined us for this remarkable evening. We're excited for future collaborations and events like this!
 
I #LifeAtBiofourmis #OktaEvent #BradMarchand #BostonBruins #LegacyClubofBoston #ITSecurity #OrganizationalSuccess #DigitalHealth

We are pleased to announce that that WellSpan Health has chosen Biofourmis to support the enterprise-wide expansion and management of a bundled program that includes hospital-level and post-acute care at home.

A leading, innovative health system, WellSpan Health has a clear care-at-home vision and strategy and recognizes that a single, comprehensive care solution that enables scalable outcomes based on their unique needs during their care-at-home evolution is essential for driving a thriving program.

We look forward to growing with WellSpan and supporting an optimal care experience for patients throughout Central Pennsylvania and Northern Maryland.

For more details, read our latest press release: https://lnkd.in/gKrGxD3u I #HospitalAtHome #CareAtHome #CareAnywhere #DigitalHealth #PatientOutcomes #PostAcuteCare

Congress is wading into the question of whether the hospital-at-home model of care should be made permanent.

A bipartisan bill was introduced that would set up a pilot program to test whether the Acute Hospital Care at Home initiative could be expanded to new populations beyond those needing acute care services. The At Home Observation and Medical Evaluation (HOME) Services Act, if passed, would give the strategy some life beyond the planned December 31, 2024, expiration date for the Medicare waiver that supports the program.

HealthLeaders’ Eric Wicklund shares the full story: https://lnkd.in/eJBt7nV3 I #HospitalAtHome #AcuteCareAtHome #AtHOMEServicesAct

We are pleased to announce FOUR new agreements with top pharmaceutical companies!

Driven by Biofourmis’ proven leadership and expertise in digital biomarker development and the strength of its comprehensive, device- and location-agnostic clinical trial solution, the new engagements focus on oncology therapies, further expanding Biofourmis’ already diverse therapeutic portfolio that includes cardiovascular, pain, women’s health, and immunology.

We are in Orlando for SCOPE Summit this week. Stop by booth #716 to learn more about how we are giving pharma partners the opportunity to accelerate drug research, make therapeutics safer and more effective, and scale digital drug companions.

https://lnkd.in/efsQcg7f I #SCOPESummit #SCOPE2024 #ClinicalTrials #DigitalHealth #DigitalMeasures #DigitalClinicalTrials #DigitalEndpoints #PharmaNews

We are LIVE from Orlando for SCOPE 2024!

Stop by Biofourmis booth #716 to learn how Biofourmis is enabling clinical trials anywhere with our digital solutions and harnessing physiologic data to develop digital biomarkers and digital endpoints.

Today, don’t miss Biofourmis Chief Operating Officer Jaydev Thakkar’s panel discussion with leaders from Takeda and Pfizer on the evolving landscape of digital measures in clinical trials at 12:55 PM located in room St John's 26/27.

I #SCOPESummit #SCOPE2024 #ClinicalTrials #DigitalHealth #DigitalMeasures #DigitalClinicalTrials #DigitalEndpoints Cambridge Healthtech Institute

Attending ViVE?

🤝 Meet our team at Booth #1924, where you can experience a demo of our industry-leading platform that is revolutionizing the delivery of care and drug development across the care continuum.

👍 Or follow us here during the event, taking place in Los Angeles from February 25-28.

We’d love to meet with you. I #ViVE24 #ViVE2024 #DigitalClinicalTrials #HospitalAtHome #FutureOfHealthcare #Pacesetter Maulik Majmudar, M.D. Ross Armstrong David Plummer Tyler Combs Amelia Favorite Ashley Hefner Thomas Demetriades Andrew Slotnick Doug Burgener

Metric
Company Name	Biofourmis	Cezar Health	Joint Medical Company	Synergy CHC Corp.
Symbol				SNYR
MSH ID	COM:BIOFOURMIS	COM:CEZARHEALTH	COM:JOINTMEDICALKW	COM:SYNERGYCHC
Market	PRIVATE	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Healthcare Technology	Medical Equipment and Supplies	Medical Equipment and Supplies
Country	US	PS	KW	US
Stage
Employee Count	451			36
Website	biofourmis.com	cezarhealth.com	jointmedicalkw.com	synergychc.com
LinkedIn	biofourmis			synergy-chc-corp
Founders

Metric
Market Cap				48.48M
Enterprise Value
Monthly Web Traffic				1.76K
Web Traffic Growth				0.83
Valuation
Raised Capital				10M

Metric
Revenue				42.78M
Revenue (LTM)
Revenue (NTM)
Gross Profit				32.08M
EBITDA				10.84M
Operating Income				10.81M
Net Income				6.34M
EPS				0.07
Diluted EPS				0.07
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin				0.73
Operating Profit Margin				0.19
EBITDA Margin				0.25
Net Profit Margin				0.06
Return on Equity
Return on Assets				0.07
Return on Capital Employed				9.90

COM:BIOFOURMIS

Biofourmis

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio				-0.10
P/B Ratio				-0.17
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio				12.31
EV Multiple				59.33

Metric
Days Sales Outstanding				20.83
Days Payables Outstanding				1.05
Days Inventory Outstanding				375.05
Operating Cycle				469.08
Cash Conversion Cycle				469.08
Asset Turnover				1.43

Metric
Operating Cash Flow				421.73K
Free Cash Flow				421.73K
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield				3.28

Metric
Cash & Equivalents				632.53K
Accounts Receivable				1.38M
Inventory				3.73M
Goodwill
Debt to Capitalization				5.59
Debt to Assets				1.10
Current Ratio				0.50
Quick Ratio				0.76

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue				0.01
R&D to Revenue
SG&A to Revenue				0.19